slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,539
Current window 90,511-90,540
Pages 3,685
Rows per page 30
Component
90,511-90,540 of 110,539
04
The slide uses a color-coded grid to map product categories to specific industry applications.Lakeland Bancorp | Results Presentation Deck | 14 slides · Lakeland
Conference presentation Investor relations Loop · Voice Of Customer1 hit
08
Lakeland Bancorp | Results Presentation Deck | 14 slidesLakeland Bancorp | Results Presentation Deck | 14 slides · Lakeland
Conference presentation Investor relations Beat · Key Takeaways1 hit
09
Includes a footnote regarding the acquisition closing date.Lakeland Bancorp | Results Presentation Deck | 14 slides · Lakeland
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
09
Uses scientific visualization to illustrate the drug's impact on brain function.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
The slide uses a process flow diagram to illustrate the biological mechanism of action.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
Uses a nested circle diagram to visualize the funnel of patients from total prevalence to treatment non-responders.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
13
The slide presents clinical trial data (STAI-G scores) over 24 weeks, highlighting significant symptom reduction and safety profile.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Beat · Traction1 hit
18
The slide outlines the strategic rationale for a specific clinical trial phase.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
21
The slide uses a biological process diagram to explain the drug's mechanism of action (MOA).MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
23
The slide uses a bar chart to demonstrate the therapeutic index advantage of the R-enantiomer.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
24
The chart shows improvement in social anxiety at 1 month and 6 months, indicating durability of effect.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
26
The slide highlights three pillars of collaboration: discovery engine, drug delivery, and clinical testing.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
27
The slide highlights a strategic partnership and the resulting research pipeline.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
31
The slide uses a bulleted list format to highlight core business strengths and specific drug development programs (MM-120 and MM-402).MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
06
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
07
The slide uses a 'Target vs Status' framework to demonstrate progress.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
08
The slide outlines specific milestones including FDA approval, manufacturing scale-up, US market entry, and D2C expansion.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
11
The slide uses a pie chart graphic as a visual metaphor for market segmentation, though it does not contain actual data.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
13
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
14
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
17
The slide outlines CE marking in Europe and the ongoing FDA PMA review process, including specific audit and inspection history.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
20
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
21
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
22
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
07
The slide uses a Gantt-style chart to visualize clinical trial progress for seven distinct programs.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
12
TEAE = Treatment-Emergent Adverse Events. Data compares Navacaprant vs Placebo (n=102 each).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · EvidenceLoop · Jobs To Be Done1 hit
13
Includes a timeline diagram for the randomized, double-blind treatment phase and a summary table of inclusion criteria and endpoints.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
15
Includes qualitative expert testimonials regarding pricing and market access.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Market Sizing1 hit
16
The diagram illustrates a decision-tree process based on clinical trial outcomes.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
17
Includes a biological pathway diagram showing V1aR antagonism and downstream signaling effects.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit